FDA OK's Novartis' oral iron chelator Jadenu
This article was originally published in Scrip
Executive Summary
Novartis won the FDA's approval to market Jadenu (deferasirox) as a treatment for chronic iron overload, a life-threatening cumulative toxicity that results from blood transfusions required to treat sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions.